XML 98 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Stock Plans and Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Schedule of Assumptions Used in Determining Fair Value of Stock Option Grants

The fair value of stock option grants and ESPP are determined using the Black-Scholes option pricing model with the following weighted average assumptions. In addition, the fair value per share on grant date is presented below: 

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Employee Stock Options:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair value per share on grant date

 

 

 

 

$58.75

 

 

 

 

 

$33.06 - $58.75

 

Expected term (in years) (1)

 

 

 

 

 

6.00

 

 

 

 

 

 

6.00

 

Expected volatility (2)

 

 

 

 

45%

 

 

 

 

 

45% - 50%

 

Risk-free interest rate (3)

 

 

 

 

2.72%

 

 

 

 

 

2.72% - 2.98%

 

Dividend rate (4)

 

 

 

 

0%

 

 

 

 

 

0%

 

Employee Stock Purchase Plan:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years) (1)

 

 

0.50

 

 

 

0.50

 

 

 

0.50

 

 

 

0.50

 

Expected volatility (2)

 

45%

 

 

45% - 50%

 

 

45%

 

 

45% - 60%

 

Risk-free interest rate (3)

 

1.93% - 2.52%

 

 

1.89% - 2.33%

 

 

1.93% - 2.52%

 

 

1.18% - 2.33%

 

Dividend rate (4)

 

0%

 

 

0%

 

 

0%

 

 

0%

 

 

(1)

The expected term represents the period that the stock-based compensation awards are expected to be outstanding. Since the Company did not have sufficient historical information to develop reasonable expectations about future exercise behavior, the Company used the simplified method to compute expected term, which reflects the average of the time-to-vesting and the contractual life;

(2)

The expected volatility of the Company’s common stock on the date of grant is based on the weighted average of the Company’s historical volatility as a public company and the volatilities of publicly traded peer companies that are reasonably comparable to the Company’s own operations;

(3)

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term of the grant; and

(4)

The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.

Schedule of Stock Option Activity

A summary of activities under the 2008 Plan and the 2016 Plan is shown as follows for the year ended December 31, 2018 and the nine months ended September 30, 2019:

 

 

 

Stock options

outstanding

 

 

Weighted

average

exercise price

 

Outstanding at December 31, 2017

 

 

2,440,290

 

 

$

16.55

 

Granted

 

 

557,896

 

 

 

35.01

 

Exercised

 

 

(778,370

)

 

 

13.04

 

Forfeited

 

 

(473,743

)

 

 

22.35

 

Outstanding at December 31, 2018

 

 

1,746,073

 

 

 

22.43

 

Granted

 

 

 

 

 

 

Exercised

 

 

(851,467

)

 

 

18.58

 

Forfeited

 

 

(96,758

)

 

 

23.95

 

Outstanding at September 30, 2019

 

 

797,848

 

 

 

26.36

 

 

Schedule of Stock Options Outstanding and Options Exercisable and Vested

Stock options outstanding, and options exercisable and vested are as follows:

 

Outstanding as of

September 30, 2019

 

 

Remaining

contractual

life (years)

 

 

Weighted

average

exercise price

 

 

Exercisable

as of

September 30,

2019

 

 

Remaining

contractual

life (years)

 

 

Weighted

average

exercise price

 

 

797,848

 

 

 

7.65

 

 

$

26.36

 

 

 

222,219

 

 

 

6.53

 

 

$

18.21

 

 

 

Outstanding as of

December 31, 2018

 

 

Remaining

contractual

life (years)

 

 

Weighted

average

exercise price

 

 

Exercisable

as of

December 31,

2018

 

 

Remaining

contractual

life (years)

 

 

Weighted

average

exercise price

 

 

1,746,073

 

 

 

7.89

 

 

$

22.43

 

 

 

579,319

 

 

 

6.73

 

 

$

8.13

 

Schedule of Vested and Nonvested Stock Option Activity

Vested and nonvested stock option activity was as follows:

 

 

 

Vested

 

 

Nonvested

 

 

 

Options

outstanding

 

 

Weighted

average

exercise

price

 

 

Options

outstanding

 

 

Weighted

average

exercise

price

 

Outstanding at September 30, 2019

 

 

222,219

 

 

$

18.21

 

 

 

575,629

 

 

$

29.50

 

Outstanding at December 31, 2018

 

 

579,319

 

 

$

8.13

 

 

 

1,166,754

 

 

$

26.58

 

 

Summary of Activity in Connection with RSUs, Market-based RSUs and RSUs

A summary of activity in connection with the Company’s RSUs, market-based RSUs and PSUs for the nine-month period ended September 30, 2019 is as follows:

 

 

 

Number of Shares

 

Outstanding as of December 31, 2018

 

 

904,033

 

Granted

 

 

687,817

 

Vested

 

 

(271,853

)

Forfeited

 

 

(75,181

)

Outstanding as of September 30, 2019

 

 

1,244,816

 

 

Summary of Stock-Based Compensation Expense

The Company recorded the total stock-based compensation expense as follows (in thousands):

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Cost of revenue

 

$

509

 

 

$

312

 

 

$

1,356

 

 

$

1,877

 

Sales and marketing

 

 

2,423

 

 

 

1,180

 

 

 

7,338

 

 

 

7,147

 

Research and development

 

 

1,732

 

 

 

1,091

 

 

 

5,560

 

 

 

5,606

 

General and administrative

 

 

3,637

 

 

 

958

 

 

 

9,840

 

 

 

5,627

 

Total

 

$

8,301

 

 

$

3,541

 

 

$

24,094

 

 

$

20,257